🔗 Share this article WHO Issues Alert Over Severe Scarcity of Weight-Loss Injections Under a tenth of patients who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it issues its initial recommendations on the medications. Considering more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs. According to projections, more than two billion could be obese by 2030 without intervention. "Our latest guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and supply-chain constraints are significant obstacles to widespread availability to the jabs that can assist patients in reducing considerable weight, says the agency. GLP-1 Therapy Supply Crisis Even in the current most optimistic case, the production of such drugs might only reach around 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation calls on nations and manufacturers to expand access, via measures such as voluntary licensing. Exclusive production rights on semaglutide – the core component of a leading brand – is scheduled to end in multiple countries in 2026. The Way Obesity Drugs Function GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake. People usually begin shedding pounds after several weeks of starting on the weekly injections. Studies points to patients may see weight return after a year of stopping the drug, because their typical appetite come back. Being carrying excess weight raises your risk for experiencing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Excess weight impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
Under a tenth of patients who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it issues its initial recommendations on the medications. Considering more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs. According to projections, more than two billion could be obese by 2030 without intervention. "Our latest guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and supply-chain constraints are significant obstacles to widespread availability to the jabs that can assist patients in reducing considerable weight, says the agency. GLP-1 Therapy Supply Crisis Even in the current most optimistic case, the production of such drugs might only reach around 100 million people – less than 10% of eligible patients, as stated by the WHO. The recommendation calls on nations and manufacturers to expand access, via measures such as voluntary licensing. Exclusive production rights on semaglutide – the core component of a leading brand – is scheduled to end in multiple countries in 2026. The Way Obesity Drugs Function GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake. People usually begin shedding pounds after several weeks of starting on the weekly injections. Studies points to patients may see weight return after a year of stopping the drug, because their typical appetite come back. Being carrying excess weight raises your risk for experiencing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Excess weight impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.